Secretive Rampart Bioscience closes after pursuing non-viral gene therapynews2026-01-08T17:59:21+00:00January 8th, 2026|Endpoints News|
Tessera Therapeutics to lay off 90 employees, according to documentnews2026-01-08T12:29:39+00:00January 8th, 2026|Endpoints News|
Beacon Therapeutics adds $75M in push to succeed where J&J failed in vision treatmentnews2026-01-08T12:00:44+00:00January 8th, 2026|Endpoints News|
As gene editing tools multiply, the hunt for the final technology continuesnews2025-12-29T17:02:50+00:00December 29th, 2025|Endpoints News|
Catalent handed two Form 483s for Maryland gene therapy sitesnews2025-12-19T12:25:40+00:00December 19th, 2025|Endpoints News|
Addition Therapeutics raises $106.5M for all RNA ‘jumping gene’ therapiesnews2025-12-17T13:22:29+00:00December 17th, 2025|Endpoints News|
J&J backs financing round for Stanford CAR-T cell therapy spinout Link Cellnews2025-12-16T16:03:20+00:00December 16th, 2025|Endpoints News|
Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trialnews2025-12-15T16:10:23+00:00December 15th, 2025|Endpoints News|
Western genetic medicine makers turn to Chinese investigator-initiated trialsnews2025-12-15T12:30:18+00:00December 15th, 2025|Endpoints News|
Tenaya targets $60M offering after heart disease pipeline updatesnews2025-12-12T12:04:38+00:00December 12th, 2025|Endpoints News|
